NCT00300287View on ClinicalTrials.gov

A 56-Week Extension to a Clinical Study to Assess the Efficacy and Safety of Vildagliptin Compared to Placebo in Drug Naive Patients With Type 2 Diabetes and Mild Hyperglycemia

PHASE3CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

February 20, 2006

Primary Completion Date

June 26, 2007

Study Completion Date

June 26, 2007

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Vildagliptin

Trial Locations (1)

Unknown

Investigative Sites

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY

NCT00300287 - A 56-Week Extension to a Clinical Study to Assess the Efficacy and Safety of Vildagliptin Compared to Placebo in Drug Naive Patients With Type 2 Diabetes and Mild Hyperglycemia | Biotech Hunter | Biotech Hunter